Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A known ✓ | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 4/20 | 0.90 |
| ▸ | TP53 | P04637 | 1/20 | 0.90 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.90 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.90 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.50 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.44 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL16752517 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL363366 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL612484 | 1.00 | — | — | |
| Fumaric Acid SCHEMBL8557756 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL793773 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL10796092 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL7337222 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL4617429 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL12474192 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL363367 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5164397-A | Hypotensive | SYNTHELABO (FR) | 1992-11-17 | — | — | US | claimed |
| CN-117545739-A | Novel N, N-dimethyltryptamine salt and crystalline salt forms | 阿泰治疗公司 | 2024-02-09 | — | — | CN | disclosed |
| US-9789102-B2 | H3 receptor antagonist for use in the treatment of alzheimer's disease | SANOFI (FR) | 2017-10-17 | — | — | US | disclosed |
| EP-2833887-B1 | AN H3 RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE | SANOFI SA (FR) | 2016-12-28 | — | — | EP | disclosed |
| US-20160256449-A1 | H3 RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE | SANOFI (FR) | 2016-09-08 | — | — | US | disclosed |
| EP-3043799-A1 | AN H3 RECEPTOR ANTAGONIST COMBINED WITH A CHOLINESTERASE INHIBITOR FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE | SANOFI (FR) | 2016-07-20 | — | — | EP | disclosed |
| EP-2445899-B1 | NOVEL FUMARATE SALTS OF A HISTAMINE H3 RECEPTOR ANTAGONIST | SANOFI SA (FR) | 2016-05-11 | — | — | EP | disclosed |
| US-20160101099-A1 | H3 RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE | SANOFI (FR) | 2016-04-14 | — | — | US | disclosed |
| WO-2015032966-A1 | AN H3 RECEPTOR ANTAGONIST COMBINED WITH A CHOLINESTERASE INHIBITOR FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE | SANOFI (FR) | 2015-03-12 | — | — | WO | disclosed |
| EP-2833887-A1 | AN H3 RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE | SANOFI (FR) | 2015-02-11 | — | — | EP | disclosed |
| EP-0369388-A1 | Hydroxy-1,2,3,4-tetrahydroaminoacridines, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1990-05-23 | — | — | EP | disclosed |
| US-4885302-A | 2-((4-Piperidyl)methyl)-1,2,3,4-tetrahydroisoquinoline derivatives, their preparation and their application in therapy | SYNTHELABO, 58, RUE DE LA GLACIERE - 75013 PARIS | 1989-12-05 | — | — | US | disclosed |
| US-4870074-A | Substituted benzamide derivatives, for enhancing gastrointestinal motility | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1989-09-26 | — | — | US | disclosed |
| EP-0282133-A2 | 1-alkyl substituted benzimidazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-09-14 | — | — | EP | disclosed |
| EP-0243959-A1 | Substituted benzamide derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same | Dainippon Pharmaceutical Co., Ltd. (JP) | 1987-11-04 | — | — | EP | disclosed |
| US-4689327-A | N-substituted-2-[2-[2-(4-phenylpiperazine-1-yl)ethoxy]phenyl]-thiazolidine-3-carboxamides useful as cardiotonic agent | TANABE SEIYAKU CO., LTD. (JP) | 1987-08-25 | — | — | US | disclosed |
| US-4647565-A | 2-(2-quinazolinylaminoalkoxymethyl)-1,4-dihydropyridine derivatives as cardiovascular agents | PFIZER INC. (US) | 1987-03-03 | — | — | US | disclosed |
| EP-0168151-A1 | Dihydropyridine cardiovascular agents | Pfizer Limited (GB) | 1986-01-15 | — | — | EP | disclosed |
| US-4562255-A | HYPOTENSIVE AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1985-12-31 | — | — | US | disclosed |
| EP-0070097-A1 | 1,2,4-Triazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 1983-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160101099-A1 | H3 RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE | HRH3, HRH4, HRH1 | KMT2A 47/4885MEN1 4026/4885TSHR 270/4885 |
| US-20160256449-A1 | H3 RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE | HRH3, HRH4, H1-2 | KMT2A 28/4885MEN1 3270/4885TSHR 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.